Our hosts explore why ketone monitoring matters, what pharmacists should know about Libre Duo, and how patient education can support proactive care management.
|Articles|January 24, 2005
BREAKING NEWS...
The black eye the FDA received recently over its handling of Vioxx (rofecoxib, Merck) and antidepressants hasn't slowed the agency's new drug approval rate for 2004. It cleared 31 new molecular entities (NMEs) last year, up from 21 in 2003.
Advertisement
Advertisement
Related to this article
Mark Ey, RPh, details the patient-focused factors of the ACCESS to Pharmacy Care Program and the ways in which valued care translates to reimbursement.
A new option for adults who have experienced stroke will now be available to further reduce future risk.
Investigators believe triglyceride testing could improve viral sepsis risk more broadly based on study findings.
Nicholas Rebold, PharmD, MPH, BCIDP, AAHIVP, explains how education eases inpatient switches, and how the protocol cuts costs and simplifies workflow.
Findings from a meta-analysis of over 125 clinical trials led the agency to require a class-wide label change.
Gilead’s current lenacapavir patent is what makes Dr Reddy’s Laboratories’ formulation tentative.
Mark Ey, RPh, from NCPA, joins to discuss the opportunities for independent pharmacies within the ACCESS to Pharmacy Care Program.
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Approves Asundexian, First FXIa Inhibitor for Stroke Prevention
2
The Outcome-Based Program That Could Reshape Pharmacists’ Roles
3
US Lost Over 3000 Pharmacies From 2022 to 2024, Mostly Chains
4
FDA Grants Tentative Approval for First Generic Lenacapavir
5